


Journal Pre-proof

Chromatin dynamics and histone modifications in the intestinal microbiota-host crosstalk

Rachel Fellows, Patrick Varga-Weisz



PII: S2212-8778(19)30956-1

DOI: <https://doi.org/10.1016/j.molmet.2019.12.005>

Reference: MOLMET 925

To appear in: *Molecular Metabolism*

Received Date: 13 October 2019

Revised Date: 8 December 2019

Accepted Date: 10 December 2019

Please cite this article as: Fellows R, Varga-Weisz P, Chromatin dynamics and histone modifications in the intestinal microbiota-host crosstalk, *Molecular Metabolism*, <https://doi.org/10.1016/j.molmet.2019.12.005>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier GmbH.

Chromatin dynamics and histone modifications in the intestinal microbiota-host crosstalk

Rachel Fellows¹ and Patrick Varga-Weisz^{1,2}

1: Babraham Institute, Babraham, Cambridge CB22 3AT, UK

2: School of Life Sciences, University of Essex, Colchester, CO4 3SQ, UK

Correspondence: Patrick.varga-weisz@essex.ac.uk

Abstract

Background

The microbiota in our gut is an important component of normal physiology that has co-evolved with us from the earliest multicellular organisms. It is, therefore, not surprising that there is an intimate crosstalk between the microbial world in the gut and the host. Genome regulation through microbiota-host interactions not only affect the host's immunity, but also metabolic health and resilience against cancer. Chromatin dynamics of the host epithelium involving histone modifications and other facets of the epigenetic machinery play an important role in this process.

Scope of Review

In this review we will discuss recent findings relevant to how chromatin dynamics shape the crosstalk between the microbiota and its host, with special focus on the role of histone modifications.

Major Conclusions

Host-microbiome interactions are important evolutionary drivers and are, thus, expected to be hardwired into and mould the epigenetic machinery in multicellular organisms. Microbial derived short chain fatty acids (SCFA) emerge as a dominant

determinant in microbiome-host interaction and the inhibition of histone deacetylases (HDACs) by SCFA is a key mechanism in this process. The discovery of alternative histone acylations, such as crotonylation, in addition to the canonical histone acetylation reveals a new layer of complexity in this crosstalk.

The epigenome is shaped by the environment

Each cell in the body of a multicellular eukaryotic organism usually has essentially the same genome in its nucleus, packaged into a highly complex superstructure known as chromatin. The basic building block of chromatin is the nucleosome, composed of eight core histones (H2A, H2B, H3, H4) around which DNA winds in almost two turns. An additional linker histone H1 'seals off' this structure. Histone tails, normally unstructured but highly conserved peptide components of the histones, protrude from the core nucleosome body and are subject to a plethora of posttranslational modifications (PTMs). These various histone PTMs are critical components of gene and genome regulatory mechanisms and are thought to constitute something of a 'regulatory language' (the 'histone code'), in part by creating binding sites for effector proteins, often called 'readers' (reviewed in: [1–3]). Histone acetylation is a paradigm histone PTM. This modification occurs on the epsilon amino groups of lysine residues on N-terminal tails of predominantly histones H3 and H4 and is associated with permissive, transcriptionally active chromatin. This modification is mediated by histone acetyltransferases (HATs, 'writers') and reversed by histone deacetylases (HDACs, 'erasers').

Histone lysine methylations are PTMs that have also been well studied, but here the functional context is more complex compared to acetylation. For example, trimethylation of histone H3 at lysine 4 (H3K4me3) is strongly linked to active genes,

whereas trimethylation of histone H3 at lysines 9 (H3K9me3) or 27 (H3K27me3) are part of various gene repressive pathways [4].

The structure of nucleosomes are altered by a plethora of additional proteins of which ATP-dependent nucleosome remodelling factors are an important group (reviewed in [5,6]). These factors can catalyse the eviction or restructuring of nucleosomes, for example by histone dimer eviction or exchange of histone variants. These factors also affect the posttranslational modifications of histones, possibly by facilitating these enzymatic steps in a nucleosomal context.

In addition to histones, DNA itself is modified, most commonly methylation of carbon-5 position of cytosines at CpG dinucleotide sequences. Histone and DNA modifications are important components of epigenetic mechanisms, which not only allow cells to differentiate into many cell types from one genome blueprint, but also form a part of a cellular 'memory' [7]. This 'memory' is not only essential for a cell to 'remember' its identity, but it also constitutes a mechanism by which a cell can integrate external cues, such as environmental influences. Other components of the epigenetic machinery are transcription factor networks and noncoding RNAs, including long noncoding RNAs and micro RNAs. Exactly what constitutes an epigenetic mechanism or what should be called 'epigenetic' has been subject of some debate, but we feel a practical, non-dogmatic approach is useful and we consider everything that moulds the functional output of the genome without changing the underlying DNA sequence to be 'epigenetic', remembering that 'epi' stems from Greek for 'on top of'.

Our microbiota are very dominant environmental factors that our bodies have to deal with, affecting health and disease. In this review we will discuss recent work investigating how the gut microbiota shapes the epigenome. This is a dynamic and

complex field and there have been a number of recent reviews covering various aspects [8–14]. We focus here on how this crosstalk shapes the host's genome function through histone modifications and we discuss very recent papers. As this topic is complex and brings together several fields, we have a 'glossary' box to summarise or explain several critical terms (Table 1).

The microbial world in us

Our world is permeated, if not dominated, by microbes and we find microbes thriving in the most hostile environments on earth. Thus, it is not surprising to find that our bodies are also home to a staggering number and diversity of microbes, including bacteria, archaea, protists, yeasts and viruses. Technological developments, especially next generation sequencing based methods of metagenomics have revolutionised our understanding of the microbial world, including our microbiota. We have learned that complex ecosystems of microbes cover many mucosal surfaces of our body, such as the skin, gut, vagina, lungs, uterus and bladder [15–18].

The microbiota and host have coevolved from the earliest multicellular organisms onwards and it has been argued that pressure on the host to control the microbiota has been an important evolutionary driver [19]. Thus, the host microbiome has been termed 'an ecosystem on a leash' [19]. As Foster *et al.*, wrote: "Host control over the microbes (as opposed to microbial control of the host) can be predicted, because there is only one host in the interaction, in contrast to the myriad microbes. Thus, unlike individual microbes, a host can easily influence the entire microbiome, and benefit from doing so" [19]. Therefore, while we will present evidence in this review that the microbiota manipulates the epigenetic machinery for interaction with the

host, we can expect that this interaction also shaped the epigenetic machinery during evolution.

In many mammals, including human, the greatest number of microbes are found in the colon (**Figure 1**). It is estimated that the number of microbes in the colon at least match the total number of host cells in a human [20]. The microbiota create a complex ecosystem where several species compete with, depend on or influence each other. Importantly, the microbial community in the colon is highly diverse with at least ~ 1000 different species. Despite some redundancy in function between species, this means that the combined microbial 'genome' is more than 100-fold greater than the host's. This has important implications to the host, as the microbiota contain unique genes that are absent in the host's genome. Many of these genes encode enzymes that break down dietary components, such as complex carbohydrates, and make these absorbable and available to the host. In this way, the microbiota make an important contribution to the host's extraction of nutrients and energy from the diet [21]. This can be seen in germ-free mice that are usually leaner than their microbiota containing counterparts [22]. In addition to helping in the digestion of food, bacteria also synthesize essential vitamins and are key in training the immune system. Furthermore, our normal, commensal microbiota protect us from pathogenic microbes, in part by simply competing them out of space and nutrients. Thus, the microbiota exert an important and largely beneficial role in our life. In their role in digesting food and generating vitamins, the microbiota could be considered almost an organ in our body. This notion is strengthened if one considers that structures in the gut, such as the caecum, evolved to house the microbiota. Yet, this would be a highly dynamic organ, not only changing dramatically in size depending on food intake and digestive status, but also in the species composition of microbes.

In fact, the microbial composition differs from person to person because the microbiota composition is strongly affected by nutrition, lifestyle and other factors [23,24].

Furthermore, the microbiome composition evolves during life time, from its acquisition during and after birth, maturing after weaning and changing even into old age [24]. However, the microbiota can turn into the enemy within us. Not only can we ingest harmful bacteria, such as *Salmonella* that invade and poison our body [25], our body can also overreact to the presence of the microbiota in the gut, for example, as a result of genetic predisposition. This can lead to inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis [26]. Furthermore, the microbiota have been identified as contributing factor in cancer processes, especially gastric and colon cancers. The role of *Helicobacter pylori* in gastric cancer is an illustration for this [27].

In summary, the microbiota are a dominant force in our lives and understanding how microbiota-host interactions are regulated is important.

Crosstalk microbiota-host through microbial metabolites

The crosstalk between microbiota and host occurs through a large variety of molecules, such as bacterial structural components and metabolites. Bacterial cell wall components or flagellar proteins are recognized by the host's cells through specific receptors (so called pattern recognition receptors, PRRs) in innate immune responses. Toll-like receptors are well studied PRRs. The microorganism-associated molecular patterns (MAMPs) include lipopolysaccharides, flagellin, and peptidoglycans. These initiate signalling cascades, e.g., leading to an anti-bacterial response through generation of cytokines, chemokines and/ or anti-bacterial peptides (reviewed in [28,29]). Another important mechanism by which the

microbiota interact with the host is through the generation of bioactive molecules that are taken up in the host's cells and affect cellular functions, especially gene regulation [29]. There are several key metabolites that have been studied in this context, which include short chain fatty acids (SCFA), polyamines, vitamins and aryl hydrocarbon receptor (AHR) ligands. **Figure 2** summarises some of these bacterially derived molecules and their impact on the host.

The AHR is a nuclear receptor type of transcription factor that is activated by binding to diverse ligands, including xenobiotics, plant or bacterial metabolites or bacterial pigments [30–32]. AHR function has been shown to be required for intestinal immunity in mice by maintaining intestinal intraepithelial lymphocytes [30].

Bacteria synthesize several vitamins such as B12 (cobalamin), riboflavins and folate [33]. As folate is required for DNA and histone methylation, the commensal bacteria have a potentially broad impact on epigenetic mechanisms [34,35].

Polyamines (PA) such as spermine, spermidine and putrescine are essential for life in eukaryotes and prokaryotes, being involved in many processes, such as gene expression, chromatin structure regulation, stress response, differentiation and proliferation (for review: [36]). Normally, PA are derived from the diet and absorbed by the small intestine, but can also be generated by the microbiota in considerable amounts in the colon, where they are thought to support epithelium health [36]. How microbial PA affect the host's chromatin is poorly understood.

SCFA constitute a major class of bacterial metabolites. They are generated by the microbiota through the fermentation of complex carbohydrates as a metabolic waste product in the colon (and in many animals in the caecum) to large amounts and have a profound impact on the host's physiology (reviewed in: [37]). The major microbial derived SCFA are acetate, propionate and butyrate. Estimates of SCFA

concentration vary between studies and different diets, but Rombeau and associates approximated SCFA concentrations in the content of the human colon to be 75 mM for acetate, 30 mM for propionate and 20 mM for butyrate [38]. These SCFA are generated by several bacterial species and there is cross-feeding between bacterial species, e.g. acetate and lactate producing *Bifidobacterium* species have been shown to feed the butyrate producing *Faecalibacterium prausnitzii* [39].

While acetate and propionate are released into the blood stream through the portal vein, butyrate is mostly absorbed and metabolized by the colon epithelium, which constitutes the preferred energy source in this tissue [21]. In fact, the absence of microbiota in germ-free mice and, therefore, the lack of SCFA causes a complete remodelling of metabolism in the colon epithelium with a dramatic upregulation of autophagy to compensate for the loss of microbial SCFA [21]. Antibiotic treatment to deplete microbiome confirms the importance of the microbiota in energy generation and metabolism [40]. The oxidation of butyrate in the epithelium affects O₂ levels, causing activation of the oxygen sensor HIF1, which in turn affects the response to pathogens [41,42]. Butyrate inhibits cellular proliferation of intestinal stem/progenitor cells at physiologic concentrations and it has been suggested that the epithelial cellular anatomy reflects this influence, protecting the stem and proliferating cells from the effects of butyrate by sequestering them in crypts [43]. Thus, butyrate has different impacts on cells dependent on their location along the crypt axis - with stem cell niche being relatively depleted of butyrate while villus cells use butyrate as a principal carbon source [43].

Butyrate and propionate are effective HDAC inhibitors at the concentrations that are generated in the colon and this constitutes an important mechanism by which these SCFA affect physiology. SCFA also activate G-coupled-receptors (GPCRs, also

called free fatty acid receptors, FFARs). GPR43 and 41 have been studied in this respect. In both capacities, as HDAC inhibitors and activators of GCPRs, the bacterial derived SCFA suppress inflammatory responses (reviewed in [37]). SCFA might also promote histone modifications by metabolic conversion to the acetyl-CoA and other SCFA-CoA precursors to be transferred to histones by HATS such as p300/CBP (see below, [44,45]).

Histone modification in the microbiota-host crosstalk

It has been known for decades that there is a link between fiber content of diet, production of SCFA by the microbiota and histone acetylation in the gut [46]. More recently, a study examined the effect of the microbiota and diet on histone modifications using mass spectrometry analysis [47]. The researchers employed conventionally raised, germ-free and microbiota-re-colonized (“conventionalized”) mice to address the role of the microbiota [47]. Since conventionally raised animals exhibit developmental differences versus their germ-free controls (reviewed in: [48]), the use of the conventionalized mice allowed for studying of effects related to the presence or absence of the microbiota directly. This study is important as it showed that the gut microbiota effected histone acetylation and methylation not only in the colon, but also in the liver and white adipose tissue and that generation of SCFA by the microbiota is a dominant driver of this. The researchers found that the presence of microbiota robustly promoted histone acetylation of H3 and H4 at multiple lysine residues in the various tissues, whilst changes in H3 methylation were subtle, but still significant [47]. Some histone PTMs appeared to be similarly regulated across all tissues surveyed, whilst other changes were tissue specific. Interestingly, feeding mice a diet high in fat and sucrose and low in fermentable complex carbohydrates

(HF/HS-diet, “western-style diet”) suppressed microbiota-driven SCFA production and chromatin effects observed in a fiber-rich diet. HF/HS-fed conventionally raised mice displayed higher hepatic total cholesterol and triglycerides versus diet-matched germ-free controls and chow-fed mice, showing that HF/HS feeding impacted the host’s metabolic state in a microbiota-dependent manner. The presence of microbiota and the diets manifested themselves in gene expression in the liver and many affected genes related to metabolism.

Gut microbiota altered expression of genes linked to metabolites that are required for histone PTMs. For example, expression of ATP citrate lyase (*Acly*) an enzyme essential for glucose-driven, but not acetate-driven, histone acetylation in mammalian cells [49], was decreased in conventionally raised versus germ-free mice, under both chow and HF/HS feeding [47]. This suggested that the presence of bacterial SCFA or lipids from HF/HS feeding, may suppress glucose-driven histone modification. The authors did not examine how changes of histone modifications, e.g., over promoters, are linked to changes in gene expression, e.g., by ChIP-seq. Yet, overall, this study highlights the intimate link between diet, the microbiota and genome-regulation in the whole organism.

Alternative histone acylations in the microbiota-host crosstalk

Progress in the analysis of histone PTMs by mass spectrometry has allowed the identification of a range new modifications, many of which can be summarised as alternative acylations. These include histone crotonylation, butyrylation, hydroxybutyrylation and propionylation (reviewed in: [50–52], see **Table 2** for a summary). These modifications are also linked to metabolic pathways. For example, histone crotonylation is promoted by addition of crotonic acid to cell culture media, as

crotonic acid is converted to crotonyl-CoA by the enzyme ASCC2 [53]. Histone cronylation changes the functionality of nucleosomes compared to histone acetylation as it creates specific binding platforms for YEATS domain containing chromatin remodelling factors. Although both modifications are associated with active chromatin, cronylation promoted gene expression to a greater extent than acetylation in a cell-free assay [54–56].

We used mass spectrometry to canvas PTMs, including cronylation, in histones isolated from the intestinal epithelium [57]. We found that histone cronylation is a relatively abundant modification in the intestinal epithelium (and the brain) with H3K18cr identified as the most prevalent cronylation. When we acutely depleted microbiota in mice with a 3-day course of a cocktail of antibiotics, this not only reduced luminal SCFA, but significantly affected global histone cronylation levels in the gut. We could show that butyrate acted as a histone decronylase inhibitor and found, consistent with several other studies published around that time [58,59], that class I HDACs are potent histone decronylases [57]. Therefore, our study emphasizes inhibition of HDACs through SCFA, especially butyrate, as an important mechanism for the microbiota-host crosstalk. Similar to what has been shown in other cell types, we found H3K18cr ‘peaks’ over promoter regions of many genes and its level seems to correlate with gene expression [53,57]. Interestingly, many of the genes with higher levels of cronylation over their promoters have been linked to cancer pathways. More recently, we found that promoter chromatin cronylation reflects gene expression changes dependent on microbiota (Fellows *et al.*, in revision). Thus, it appears that promoter cronylation is an important mechanism for the microbiota-host crosstalk in the gut. Our current model how bacterial derived SCFA affect histone cronylation is shown in **Figure 3**.

HDACs in microbe-host interactions

The previous sections have already highlighted the importance of HDACs in the microbiota-host crosstalk, mainly because the microbial-derived butyric and propionic acids are HDAC inhibitors. Thus, it is not surprising that HDACs were found to have a critical role in the microbiota-host crosstalk. This is well illustrated with HDAC3 in a study from the Artis lab [60]. Intestinal epithelium specific deletion of HDAC3 (HDAC3^{ΔIEC}) led to gene expression and corresponding H3K9ac level changes at affected genes and a progressive loss of Paneth cells, with evidence of Paneth cell death [60]. Paneth cells are found at the base of the small intestinal crypt, where they play a role in regulating microbiota-host interaction by secreting anti-bacterial peptides (See Fig. 1, [61]). Thus, consistent with the loss of Paneth cells, the HDAC3^{ΔIEC} mice exhibited increased translocation of bacteria through the epithelium and increased intestinal inflammation, as well as increased susceptibility to oral *Listeria monocytogenes* infection. Remarkably, Paneth cell viability was not affected in HDAC3^{ΔIEC} mice raised under germ-free conditions and alterations in the majority of HDAC3-dependent transcriptional pathways, including those involved in anti-microbial defence, were not seen. Thus, it appears that HDAC3 is required to respond to bacterial cues and translates this to a gene expression program that protects intestinal integrity. A follow-up study from the Alenghat lab demonstrated that HDAC3 mediates communication between intestinal epithelial cells and resident lymphocytes, thereby promoting resistance against infection by pathogenic microbes [62]. Whether these actions of HDAC3 occur through deacetylation of histones or other factors, or an enzymatic independent role of HDAC3 remains to be discovered.

Furthermore, it will be exciting to find out what are the bacterial cues involved in these pathways.

Sirt1 belongs to the class III group of NAD⁺ dependent deacetylases, also called sirtuins. Several sirtuins deacetylate histones, but they also have other targets. Epithelial deletion of Sirt1 led to age-dependent enhanced inflammation in one study [63], while another study reported protection against colitis and enhanced anti-bacterial defence in the intestine [64]. Both studies reported changes in the microbiota upon the Sirt1 deletion. If chromatin deacetylation is involved in these observations remains to be elucidated, deacetylation of transcription factor SPDEF was implicated in the observed activity of Sirt1 in the intestine [64].

Another class III deacetylase/ sirtuin is Sirt2. Studies of this enzyme in cultured human cell lines (epithelial cervical adenocarcinoma cell line Hela and colorectal adenocarcinoma cell line Caco2) and mouse spleen tissue showed that this enzyme has a critical role in the pathogenic infection of cells by *Listeria monocytogenes* [65]. Sirt2 is normally predominantly cytosolic, but upon infection by *Listeria monocytogenes*, it translocates to the nucleus to tightly bind to chromatin and to deacetylate H3K18ac. This, in turn, leads to repression of genes normally involved in limiting infection [65,66]. These findings highlight (1) H3K18 as a potentially critical residue in host-pathogen interaction, (2) show that a histone modifier is essential for infection by a pathogen and (3) illustrate how bacteria can subvert the host's biochemistry for their own purposes. Overall, the studies described above highlight the importance of histone deacetylation in host-microbe crosstalk. Future studies will need to address to what extent histone deacetylation processes, such as deacetylation, are important in this crosstalk, as many HDACs can remove other

acyl-groups from histones, such as HDAC1-3 acting as decrotonylases and SIRT3 as a dehydroxybutyrylase (see Table 2, [57–59,67]).

The microbiota affect histone modifications over regulatory elements in conjunction with diet

Several histone modifications are linked to regulatory elements such as promoters and enhancers. For example, H3K27ac in combination with H3K4me1 is often found over active enhancers, while H3K4me1 without H3K27ac marks poised enhancers. Therefore, such histone modification combinations are used to identify candidate enhancer elements [68]. A study from the Wade lab examined how the microbiota in combination with diet affected H3K27ac and H3K4me1 genome wide using ChIP-seq in colon epithelial cells in the mouse model [69]. Consistent with previous work, they found that an obesogenic diet markedly altered the gut microbiota. This, in turn, caused a reduction of microbial derived butyrate and changes in mouse metabolic physiology. Their findings show that the gut microbiota in combination with an obesogenic diet (high fat diet, HFD) changes the enhancer landscape with respect to these modifications and also affected binding of a critical transcription factor in the host-microbiota crosstalk, HFN4alpha, along with concomitant changes in gene expression. Furthermore, they found that many of these changes were similar to those seen in the colon cancer process. Remarkably, transplantation of the bacteria from the HFD-fed, but not from the control diet-fed mice, into germ-free mice led to recapitulation of the HFD-associated epigenetic changes. This work demonstrates how an obesogenic diet, in combination with the microbiota, may impact disease risk, potentially predisposing to cancer by activating pathways similar to those found in cancer cells. The authors speculate that the HFD microbiota is involved in

generating metabolites from the HFD that lead to an epigenetic reprogramming of the enhancer landscape, illustrating the complexity in the microbiota-diet-host interactions [69].

Epigenetics and IBD: histone H3K4me3 changes link IBD to microbiota-host interactions

In general, the causes of IBD are complex, involving triggers from the environment and genetic susceptibility of the host [26]. Aberrant microbiota-host interactions are prime candidates driving IBD and it is important to understand to what extent epigenetic pathways underlie these defective responses. Alterations in DNA methylation have already been linked to IBD [70–74], but what about other epigenetic features? A recent study mapped genes that showed changes in the histone modification H3K4me3 in intestinal epithelial cells from terminal ilea of newly diagnosed pediatric Crohn's disease (CD) patients and compared these findings with changes in gene expression [75]. Remarkably, the changes in H3K4me3 seemed to identify the CD patients more robustly than the changes in gene expression. The researchers compared these changes with those seen in H3K4me3 in ileal epithelial cells between germ-free mice and conventionally housed mice. These global analyses showed that the presence of microbiota in the gut resulted in many changes in H3K4me3 in IECs. This demonstrated furthermore that a significant proportion of the loci identified in the patients exhibited changes in the mice dependent on the presence of the microbiota, identifying an “epigenetic profile of IBD that can be primed by commensal microbes” [75]. The patient sample number in this work was relatively small, and thus, it would be very interesting to see this type of study expanded with more patients, maybe with different forms of IBD. Yet, this

study sheds new light onto pathways by which microbiota might predispose to intestinal inflammation and illustrates how epigenetic analyses can complement other approaches for identification of epithelial abnormalities.

Demethylase KDM5 and the microbiota in the gut-brain axis

There is tantalising evidence that suggests a role of the gut microbiota in intellectual disability (ID) and autism spectrum disorder diseases (ASD). Genome-wide association and family studies have implicated several chromatin remodelling factors and histone modifiers in these diseases, including members of the KDM5 family of demethylases that remove histone H3K4 methyl groups. A group of researchers took advantage of the fact that that *Drosophila* has only one KDM5 paralog (human has four KDM5 paralogues) and that this organism has a relatively simple microbiota, to examine the role of KDM5 in intellectual deficiency and autism spectrum disorder behaviour models in the fly [76]. They found that reduced levels of KDM5 in a fly *kdm5* mutant caused global increase in H3K4me3 in the gut concomitant with intestinal barrier disruption, making the gut permeable to microbes. This was accompanied by a change in the gut microbiota, including reduction of *Lactobacillus plantarum* L168, and impaired fly social behaviour. These changes were not observed in flies reared germ-free or after antibiotics treatment. Probiotic treatment of mutant flies with *Lactobacillus plantarum* L168 restored intestinal barrier function and improved social behaviour towards normal. Together, the findings indicate that ablation of KDM5 causes a change in behaviour, at least in part by altering the gut microbiota. Furthermore, the reported activities of KDM5 depended on its demethylase activity and the researchers implicated miss-regulation of innate immunity genes to an aberrant increase in H3K4me3 over their promoters. While this

study does not rule out that a non-histone target is critical in the described functions of KDM5, it is likely that chromatin regulation plays an important role in the process. It is as yet not clear exactly how the miss-regulation of the microbiota on KDM5 mutation affects social behaviour. However, the researchers implicate an increase of the neurotransmitter serotonin, which may be microbiota dependent. Interestingly, another study identified histone serotonylation in combination with methylation (H3K4me3Q5ser) as a new histone PTM linked to active genes [77]. This new modification was found to be most abundant in the brain and gut. Whether there is a link between the microbiota and histone serotonylation remains to be investigated. In summary, the study on KDM5-microbiota interaction is an exciting illustration of how chromatin dynamics links the microbiota to physiology of tissues far from the gut, opening the question if manipulation of the gut microbiota could ameliorate ID and ASD in human.

ATP-dependent chromatin remodelling factor CHD1 and host-microbiome interactions in *Drosophila*

Drosophila with its relatively simple microbiome also provided insights into the role in host-microbiome interaction of a member of another important class of chromatin factors, the ATP-dependent nucleosome remodelling factors: CHD1, which is required for the replication independent incorporation of histone H3 variant H3.3 into chromatin [78]. Following the observation that deletion of this factor led to misregulation of genes involved in immune responses, stress responses and detoxification in larvae, the group of Alexandra Lusser found that loss of CHD1 led to an increased expression of anti-microbial peptides (AMP) in the gut. However, it also rendered flies susceptible to infection by the bacterium *Pseudomonas aeruginosa*

upon ingestion of the bacteria [79]. They found that bacterial load was significantly elevated in the *Chd1* mutant flies in the gut and in the fly body outside the gut after oral infection. This suggested that the gut epithelium was much more permissible to the passage of *P. aeruginosa* and possibly other bacteria into the hemolymph, causing the flies to die. These findings suggest that a misbalance of expressed AMP and other immune factors may have led to dysbiosis and, thus, susceptibility to the *P. aeruginosa* infection. To substantiate this further, the group performed microbiome analysis using 16S rRNA sequencing [80]. This showed a loss of species diversity in the mutant flies. For example, on the family level, the bacterial community in the wildtype flies' guts of *Pseudomonadaceae*, *Enterobacteriaceae*, *Comamonadaceae* and *Staphylococcaceae* together comprised ~19% of the fly microbiota, but these families were nearly absent in the *Chd1*-mutant flies. Complementary PCR-based assays showed the loss of *Chd1* correlated with an accumulation of *Acetobacter* and a decrease of *Lactobacillus* species. These effects were age dependent, being more pronounced in younger flies. Importantly, the authors showed that *Chd1*^{-/-} flies were unable to sustain *Lactobacillus plantarum* titres after dietary supplementation. Future research needs to determine to what extent gene regulation relevant to microbe-host interaction is the direct result of chromatin remodelling by CHD1 over the genes as opposed to some indirect effects. It will also be very exciting to find out if the role of CHD1 in host-microbe interaction is conserved in mammals.

Outlook

The microbiota affect gene regulation of the intestinal epithelium in various ways, of which the generation of SCFA is a dominant pathway. Inhibition of HDACs by SCFA

is an important mechanism. As SCFA also are an important energy source in the gut, future studies need to unravel to what extent SCFA affect chromatin by providing metabolic precursors in the cell, e.g., butyryl-CoA, for mediating alternative histone acylations.

Microbiota-host interactions are fascinating and important to study. Yet, this field poses many challenges [81]. While we presented several examples in this review, where deletion of chromatin factors affected host-microbiome interactions, the extent to which the microbiome is affected by genetic variation in the general population is an area of debate and intense research [23,82]. A huge problem in studying microbiota-host interactions is the fact that the microbiota is highly dynamic and diverse. Therefore, mice in various facilities, even SOPF (specific or pathogen free), differ markedly in their microbiota, resulting, e.g., in different outcome in experimental colitis outcomes (see for example, [83]). Furthermore, mice in clean, SOPF facilities have a reduced microbiota, with consequences to their immune system and physiology [84–86]. Therefore, future studies should consider the normal rich ‘healthy’ microbiota of wild mice. These problems are even more challenging considering the human microbiome where greater diversity in genetic background, lifestyle and other factors further complicate studies of the interaction between host and microbiota.

While we focused here on the gut microbiota, mucosal surfaces in other tissues are covered with their specific microbiota. For example, the uterus has a microbiota that affects pregnancy outcomes [87]. The inter-kingdom crosstalk is important in all these compartments and regulation through chromatin dynamics is likely going to be an important facet here, too. We are only at the start of unravelling the mechanism of microbiota-host interactions, many of which have been ‘hard-wired’ into our genome

through billion years of co-evolution. In the future, more aspects of chromatin dynamics are likely to be revealed as being essential in this process.

Acknowledgements

We thank Marisa Stebegg, Mariane Font Fernandes and Mantile Tauraitė for critical reading and comments that improved the manuscript. This work was funded by the UK Medical Research Council through grant 1642099 to R.F and funding to R.F. from the Science Policy Committee at Babraham. This work was also funded through a UK Medical Research Council project grant to PVW MR/N009398/1.

Table 1: Glossary

Term	Definition and explanation
Acylation	A group of post-translational modifications made by covalently adding functional groups to amino acid residues on proteins through acyl linkages. One main type is fatty acylation, the addition of fatty acyl chains to proteins. Acylations include formylation, acetylation, propionylation, crotonylation, butyrylation, hydroxybutyrylation, malonylation, glycosylation, succinylation, benzoylation and palmitoylation.
AhR	Aryl hydrocarbon receptor is a ligand activated transcription factor which regulates a variety of cellular processes. Ligand activation causes dissociation from its chaperone HSP90 and binding to aryl hydrocarbon receptor nuclear translocator (ARNT). AhR is an important regulator of immune responses.

Anti-microbial peptides (AMPs)	A diverse group of peptides expressed as part of the innate immune host defence (therefore, also called host defence peptides, HDPs). The peptides are usually small (12-50 amino acids) and function, for example, by destabilizing the bacterial cell membrane. A group of these peptides are called defensins which are cysteine-rich cationic peptides. Some defensins are expressed by Paneth cells at the base of the crypts of the small intestine.
Bromodomain	The bromodomain is a protein motif that is conserved in eukaryotes and found in over 100 proteins. It preferentially binds acetylated lysine residues such as those found on histones.
Commensal bacteria	These bacteria are part of the microbiota, e.g., in the gut. They do not hurt the host, but also do not provide significant benefits.
Conventionalized mouse	A mouse that was initially germ-free (see below) but has been re-colonized with normal microbiota.
Epigenetics	The study of heritable phenotypic changes in gene expression without changing the underlying DNA sequence. Deriving from the Greek 'epi' meaning on or above. This term is often used to describe many DNA and chromatin associated modifications.
Gastrointestinal tract	An organ system which takes in, digests and absorbs nutrients along with removal of waste products. It comprises the mouth, esophagus, stomach, small intestine (duodenum, ileum and jejunum), caecum (and attached appendix), colon, rectum and

	anal canal.
Germ-free mouse	Germ-free animals have no microorganisms living in or on them. Generation and maintenance of germ-free mice is a challenging task. Germ-free mice are bred in isolators that block exposure to microorganisms, keeping them free of detectable bacteria, viruses, and eukaryotic microbes. Re-colonising these mice with defined microorganisms generates gnotobiotic mice. An alternative to using germ-free mice is treating mice with a cocktail of antibiotics to get rid of a majority of bacteria [22].
GPCRs	G protein coupled receptors are a large family of membrane proteins that bind a specific molecule on the extracellular side and couple to a signalling response on the intracellular side. Ligand binding triggers a conformational change that activates the alpha subunit of the G protein which releases the gamma and beta subunits to generate further signalling reactions in the cell to elicit a response.
HDAC	Histone deacetylase. HDACs should really be called lysine deacetylases (KDACs) as they also deacetylate proteins other than histones. Based on sequence homology, 18 human HDACs are grouped into four classes. Class I enzymes are comprised of HDAC1, 2, 3, and 8. Class II enzymes are HDAC4, 5, 6, 7, 9 and 10. Class III enzymes consist of seven sirtuins, which are NAD-dependent protein deacetylases and/or ADP ribosylases. Class IV contains only HDAC11, which

	<p>shares sequences similarity to both class I and II proteins. Several inhibitors against HDACs have been developed with promise in cancer therapy [88].</p>
Hemolymph	<p>The equivalent of blood in vertebrates, the hemolymph is a fluid that circulates around the interior of arthropod bodies as part of the open circulatory system to exchange materials with tissues. Arthropods include <i>Drosophila melanogaster</i>, used frequently as a model organism in biological research.</p>
Histone code	<p>The histone code hypothesis was formulated to express the idea that histone modifications, including combinations of these modifications, regulate DNA templated processes, such as transcription [89]. Furthermore, histone modifications are thought to act, at least in part, by creating binding platforms for effector proteins, such as nucleosome remodelling factors.</p>
IECs	<p>Intestinal epithelial cells line the gut lumen and form the first line of defence after the barrier of mucus layer (see Figure 1). Stem cells in the crypt base generate Paneth cells, label retaining cells, transit amplifying cells, enterocytes, enteroendocrine cells, tuft cells and goblet cells required for maintaining the epithelial niche. IECs are supported by the lamina propria.</p>
IELs	<p>Intestinal epithelial lymphocytes are T lymphocytes derived from naïve T cells in the thymus and are present in the epithelial and lamina propria layers of the intestine. Upon detection of antigens they release cytokines to kill infected</p>

	cells.
Inflammatory bowel diseases	Chronic disorders of the digestive tract associated with prolonged inflammation. Two main types are ulcerative colitis, which occurs in the colon, and Crohn's disease which can occur anywhere along the gastrointestinal tract.
MAMPs	Microbial (or pathogen) associated molecular patterns are motifs of microbial specific structures that elicit a host response. They include flagellin, lipopolysaccharide, xylanase elongation factor Tu, peptidoglycan and viral single stranded RNA.
Microbial dysbiosis	An imbalance in the microbiota associated with overrepresentation of certain bacterial species. Caused by antibiotic use, poor diet or chronic stress. There is insufficient evidence as to whether microbial dysbiosis is a direct cause of inflammatory diseases or a result of it. As the microbial species are highly variable between individuals, determining when the microbiota is in dysbiosis can be difficult. A more narrow definition describes microbial imbalance which causes disease, in line with Koch's postulates (criteria for establishing a causal relationship between a microbe and disease).
Microbiome	This term is sometimes used synonymously to microbiota. However, the narrower definition is 'the collective genomes of the microbiota in or on an organism'. The microbial genome has typically 100 times more genes than the host genome. Major phyla of the human bacterial gut microbiome are:

	Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria.
Microbiota	The community of microorganisms (bacteria, archaea, fungi such as yeasts, protozoa, viruses and phages) found in and on a multicellular organism. These microorganisms may be symbionts, commensal or pathogenic. The word microbiota is a plural term (singular would be 'microbiotum') similar to the term 'people'.
Nucleosome	The basic unit of DNA packaging consisting of an octamer of H2A, H2B, H3 and H4 histones which coil approximately 146 base pairs of DNA.
Obesogenic diet	A high fat diet given to mice to induce obesity.
PRRs	Pattern recognition receptors are a key element of the innate immune system. Receptors identify bacterial signals to enable responses to pathogenic bacteria. PRRs include Toll-like and nucleotide binding oligomerisation domain (NOD)-like, C type lectin and RIG-1 like receptors.
PTM	Post-translational modification. Chemical modification of amino acid residues after their assembly into a protein during translation by the ribosome using an mRNA template. This can alter the chemical properties of the protein or change interactions with other proteins. PTMs include acetylation, phosphorylation, hydroxylation, glycosylation, lipidation, ubiquitination, or deamidation.
SCFA	Short chain fatty acid(s). A carboxylic acid less than six carbons in length. The predominant SCFA in the intestine are

	acetate (C2), propionate (C3) and butyrate (C4). Other SCFA include formate (C1), crotonate (C4), isobutyrate (C4), valerate (C5) and isovalerate (C5).
SOPF	Specific or pathogen free. Laboratory organisms free from certain infectious agents that are capable of pathogenicity or may interfere with an experiment.
Westernised diet	A high fat, high salt diet given to laboratory mice to replicate a 'typical' diet consumed in developed countries.
Xenobiotics	A chemical compound not normally produced or consumed by an organism. These foreign compounds can be drugs, carcinogens or pesticides.
YEATS domain	Named after the domain containing Yaf9, ENL, AF9, Taf14 and Sas5 proteins, the YEATS domain is a protein motif that preferentially binds crotonylated lysine residues. This domain has been linked to chromatin structure and gene expression.




Figure 1. The structure of the small intestine and colon epithelium

The intestine has a large surface area to enable efficient absorption of nutrients from the diet. This is comprised of pocket-like crypts, containing stem cells which generate all of the necessary cell types for the intestinal epithelium. Cells develop as they move up the crypt walls before being lost by anoikis (apoptosis induced by loss of cell contact) into the gut lumen. In the small intestine, cells are lost at the top of villi which are finger like projections that further increase surface area. There are many cell types in the intestine, the absorptive enterocytes and the mucus secreting goblet cells are the most abundant. Transit amplifying cells are proliferative and lineage committed to become enterocytes. Enteroendocrine cells secrete hormones, tuft cells secrete prostanoids and opioids, and Paneth cells secrete antimicrobial peptides and support the stem cells. Label retaining cells are quiescent Paneth cell precursors [90]. The small intestine contains a single diffuse layer of mucus which is not attached to the epithelium and contains some bacteria. The colon contains inner and outer mucus layers. The inner mucus layer is compact and attached to the epithelium and is normally free from bacteria. The outer mucus layer is diffuse with an undefined border and

provides a habitat for intestinal bacteria. The colon microbiota is larger and more diverse than that of the small intestine [91]. The lamina propria is a thin layer of connective tissue which supports the epithelial cell niche. Intestinal associated immune cells, lymphatic vessels and capillaries are not shown. The muscularis mucosae, a thin layer of muscle, separates the lamina propria from the underlying submucosa (not shown). The epithelium, lamina propria and muscularis mucosa together make the mucosal layer [92]

Journal Pre-proof








Figure 2. Microbial metabolites influence host function

A non-exhaustive list of microbial generated molecules and their effects on cellular and organismal function. Some of the bacteria species that generate the specified metabolites are listed on the arrows. References for **(A)** [34,35,93–98] **(B)** [36,99] **(C)** [100,101] **(D)** [30,102] **(E)** [103–108] **(F)** [109–114] **(G)** [115,116] **(H)** [99,117–121] **(I)** [122–125] **(J)** [122,123,126–128] **(K)** [37,38,40–42,122–124,129,129–133] **(L)** [28,29,134]

Table 2: Histone acylations and their ‘writers’, ‘readers’ and ‘erasers’.

Modification	Structure	Writer	Reader	Eraser
Acetylation		p300 (CBP, p300), MYST (Tip60, MOF, MOZ, HBO1), GCN5 (GCN5, PCAF) (a)	Bromodomain (BRD2, BRD9, TAF1, CECR2), PHD (MOZ, DPF2) and YEATS (AF9, YEATS2) (b)	Zn ²⁺ dependent (HDAC1-11), NAD ⁺ dependent (SIRT1-7) (c)
Propionylation		p300/CBP, PCAF, GCN5, MOF, HBO1, MOZ (d)	Most BRDs (CECR2, BRD2-4,7,9, TAF1), MOZ, DPF2, AF9 YEATS2 (e)	SIRT1/2/3 (f)
Butyrylation		p300/CBP, PCAF, GCN5 (g)	TAF1(2), BRD7, BRD9, CECR2, MOZ, DPF2, AF9 YEATS2 (h)	SIRT1/2/3 (i)
Crotonylation		p300/CBP, MOF (j)	TAF1(2), AF9, YEATS2, MOZ, DPF2 (k)	HDAC1-3, SIRT1/2/3 (l)


β - Hydroxybutyrylation		p300/CBP (m)	MOZ, DPF2 (n)	HDAC1-3, SIRT3 (o)
----------------------------------	---	--------------	---------------	-----------------------

Table 2. Histone acylations and their modifying enzymes

Histone acylations are set down by 'writers', acyl-transferases, bound by 'readers' for downstream events and removed by 'erasers', de-acylases. References: (a) [135] (b) [136–138] (c) [139] (d) [51,140–144] (e) [145,146] (f) [147] (g) [51,140,141] (h) [50,55,56,145,146] (i) [147] (j) [148,149] (k) [50,54–56,58,145,146,150] (l) [57–59,151,152] (m) [144] (n) [146] (o) [52,56,67].




Figure 3. Current model of how microbial derived SCFA affect histone acetylation and crotonylation

The intestinal microbiota digests fibre present in dietary components, such as apples and brown bread, into SCFA. Butyrate is the main SCFA taken up by intestinal epithelial cells. Butyrate inhibits class I HDACs to reduce the removal of acetylation and crotonylation from the histone. It might also promote histone crotonylation and acetylation by metabolic conversion to the acetyl-CoA and crotonyl-CoA precursors to be transferred to histones by p300/CBP.

References

1. Castillo J, López-Rodas G, Franco L. Histone Post-Translational Modifications and Nucleosome Organisation in Transcriptional Regulation: Some Open Questions. *Adv Exp Med Biol.* 2017;966:65–92.
2. Suganuma T, Workman JL. Signals and combinatorial functions of histone modifications. *Annu Rev Biochem.* 2011;80:473–99.
3. Yun M, Wu J, Workman JL, Li B. Readers of histone modifications. *Cell Res.* 2011;21:564–78.
4. Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. *Exp Mol Med.* 2017;49:e324.
5. Varga-Weisz PD. Chromatin remodeling: a collaborative effort. *Nat Struct Mol Biol.* 2014;21:14–6.
6. Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. *Annu Rev Biochem.* 2009;78:273–304.
7. Cavalli G, Heard E. Advances in epigenetics link genetics to the environment and disease. *Nature.* 2019;571:489–99.
8. Qin Y, Wade PA. Crosstalk between the microbiome and epigenome: messages from bugs. *J Biochem.* 2018;163:105–12.
9. Krautkramer KA, Rey FE, Denu JM. Chemical signaling between gut microbiota and host chromatin: What is your gut really saying? *J Biol Chem.* 2017;292:8582–93.
10. Miro-Blanch J, Yanes O. Epigenetic Regulation at the Interplay Between Gut Microbiota and Host Metabolism. *Front Genet.* 2019;10:638.
11. Allen J, Sears CL. Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. *Genome Med.* 2019;11:11.

12. Riscuta G, Xi D, Pierre-Victor D, Starke-Reed P, Khalsa J, Duffy L. Diet, Microbiome, and Epigenetics in the Era of Precision Medicine. *Methods Mol Biol.* 2018;1856:141–56.
13. Ye J, Wu W, Li Y, Li L. Influences of the Gut Microbiota on DNA Methylation and Histone Modification. *Dig Dis Sci.* 2017;62:1155–64.
14. Woo V, Alenghat T. Host-microbiota interactions: epigenomic regulation. *Curr Opin Immunol.* 2017;44:52–60.
15. Lloyd-Price J, Mahurkar A, Rahnavard G, Crabtree J, Orvis J, Hall AB, et al. Strains, functions and dynamics in the expanded Human Microbiome Project. *Nature.* 2017;550:61–6.
16. Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, et al. Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. *Cell.* 2019;176:649-662.e20.
17. Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. *Nature.* 2014;509:357–60.
18. Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project. *Nature.* 2019;569:641–8.
19. Foster KR, Schluter J, Coyte KZ, Rakoff-Nahoum S. The evolution of the host microbiome as an ecosystem on a leash. *Nature.* 2017;548:43–51.
20. Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. *Cell.* 2016;164:337–40.
21. Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunker MK, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell Metab.* 2011;13:517–26.
22. Kennedy EA, King KY, Baldrige MT. Mouse Microbiota Models: Comparing Germ-Free Mice and Antibiotics Treatment as Tools for Modifying Gut Bacteria. *Frontiers in Physiology* [Internet]. 2018 [cited 2019 Sep 1];9. Available from: <https://www.frontiersin.org/article/10.3389/fphys.2018.01534/full>
23. Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. *Nature.* 2018;555:210–5.
24. Kundu P, Blacher E, Elinav E, Pettersson S. Our Gut Microbiome: The Evolving Inner Self. *Cell.* 2017;171:1481–93.
25. Rivera-Chávez F, Bäumlér AJ. The Pyromaniac Inside You: Salmonella Metabolism in the Host Gut. *Annu Rev Microbiol.* 2015;69:31–48.
26. Plichta DR, Graham DB, Subramanian S, Xavier RJ. Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships. *Cell.* 2019;178:1041–56.

27. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet*. 1984;1:1311–5.
28. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat Rev Immunol*. 2014;14:141–53.
29. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol*. 2016;16:341–52.
30. Li Y, Innocentin S, Withers DR, Roberts NA, Gallagher AR, Grigorieva EF, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. *Cell*. 2011;147:629–40.
31. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity*. 2013;39:372–85.
32. Moura-Alves P, Faé K, Houthuys E, Dorhoi A, Kreuchwig A, Furkert J, et al. AhR sensing of bacterial pigments regulates antibacterial defence. *Nature*. 2014;512:387–92.
33. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. *Curr Opin Biotechnol*. 2013;24:160–8.
34. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. *Adv Nutr*. 2012;3:21–38.
35. Kok DE, Steegenga WT, McKay JA. Folate and epigenetics: why we should not forget bacterial biosynthesis. *Epigenomics*. 2018;10:1147–50.
36. Tofalo R, Cocchi S, Suzzi G. Polyamines and Gut Microbiota. *Front Nutr*. 2019;6:16.
37. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell*. 2016;165:1332–45.
38. Rombeau, J.L., Kripke, S.A., Settle, R.G. *et al.* Short-chain fatty acids. Production, absorption, metabolism, and intestinal effects. *Dietary Fiber*. D Kritchevsky, C Bonfield, JW Anderson (Eds.) Plenum Press, New York; p. 317–37.
39. Ferreira-Halder CV, Faria AV de S, Andrade SS. Action and function of *Faecalibacterium prausnitzii* in health and disease. *Best Pract Res Clin Gastroenterol*. 2017;31:643–8.
40. Zarrinpar A, Chaix A, Xu ZZ, Chang MW, Marotz CA, Saghatelian A, et al. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. *Nat Commun*. 2018;9:2872.
41. Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. *Cell Host Microbe*. 2015;17:662–71.

42. Fachi JL, Felipe J de S, Pral LP, da Silva BK, Corrêa RO, de Andrade MCP, et al. Butyrate Protects Mice from *Clostridium difficile*-Induced Colitis through an HIF-1-Dependent Mechanism. *Cell Rep.* 2019;27:750-761.e7.
43. Kaiko GE, Ryu SH, Koues OI, Collins PL, Solnica-Krezel L, Pearce EJ, et al. The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites. *Cell.* 2016;165:1708–20.
44. Carrer A, Parris JLD, Trefely S, Henry RA, Montgomery DC, Torres A, et al. Impact of a High-fat Diet on Tissue Acyl-CoA and Histone Acetylation Levels. *J Biol Chem.* 2017;292:3312–22.
45. Su X, Wellen KE, Rabinowitz JD. Metabolic control of methylation and acetylation. *Curr Opin Chem Biol.* 2016;30:52–60.
46. Boffa LC, Lupton JR, Mariani MR, Ceppi M, Newmark HL, Scalmati A, et al. Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. *Cancer Res.* 1992;52:5906–12.
47. Krautkramer KA, Kreznar JH, Romano KA, Vivas EI, Barrett-Wilt GA, Rabaglia ME, et al. Diet-Microbiota Interactions Mediate Global Epigenetic Programming in Multiple Host Tissues. *Mol Cell.* 2016;64:982–92.
48. Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. *Semin Immunol.* 2007;19:59–69.
49. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. *Science.* 2009;324:1076–80.
50. Sabari BR, Zhang D, Allis CD, Zhao Y. Metabolic regulation of gene expression through histone acylations. *Nat Rev Mol Cell Biol.* 2017;18:90–101.
51. Kebede AF, Nieborak A, Shahidian LZ, Le Gras S, Richter F, Gómez DA, et al. Histone propionylation is a mark of active chromatin. *Nat Struct Mol Biol.* 2017;24:1048–56.
52. Zhao S, Zhang X, Li H. Beyond histone acetylation-writing and erasing histone acylations. *Curr Opin Struct Biol.* 2018;53:169–77.
53. Sabari BR, Tang Z, Huang H, Yong-Gonzalez V, Molina H, Kong HE, et al. Intracellular Crotonyl-CoA Stimulates Transcription through p300-Catalyzed Histone Crotonylation. *Mol Cell.* 2018;69:533.
54. Andrews FH, Shinsky SA, Shanle EK, Bridgers JB, Gest A, Tsun IK, et al. The Taf14 YEATS domain is a reader of histone crotonylation. *Nat Chem Biol.* 2016;12:396–8.
55. Li Y, Sabari BR, Panchenko T, Wen H, Zhao D, Guan H, et al. Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain. *Mol Cell.* 2016;62:181–93.
56. Zhang Q, Zeng L, Zhao C, Ju Y, Konuma T, Zhou M-M. Structural Insights into Histone Crotonyl-Lysine Recognition by the AF9 YEATS Domain. *Structure.* 2016;24:1606–12.

57. Fellows R, Denizot J, Stellato C, Cuomo A, Jain P, Stoyanova E, et al. Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases. *Nat Commun.* 2018;9:105.
58. Wei W, Liu X, Chen J, Gao S, Lu L, Zhang H, et al. Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription. *Cell Res.* 2017;27:898–915.
59. Kelly RDW, Chandru A, Watson PJ, Song Y, Blades M, Robertson NS, et al. Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo. *Sci Rep.* 2018;8:14690.
60. Alenghat T, Osborne LC, Saenz SA, Kobuley D, Ziegler CGK, Mullican SE, et al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. *Nature.* 2013;504:153–7.
61. Adolph TE, Mayr L, Grabherr F, Tilg H. Paneth Cells and their Antimicrobials in Intestinal Immunity. *Curr Pharm Des.* 2018;24:1121–9.
62. Navabi N, Whitt J, Wu S-E, Woo V, Moncivaiz J, Jordan MB, et al. Epithelial Histone Deacetylase 3 Instructs Intestinal Immunity by Coordinating Local Lymphocyte Activation. *Cell Rep.* 2017;19:1165–75.
63. Wellman AS, Metukuri MR, Kazgan N, Xu X, Xu Q, Ren NSX, et al. Intestinal Epithelial Sirtuin 1 Regulates Intestinal Inflammation During Aging in Mice by Altering the Intestinal Microbiota. *Gastroenterology.* 2017;153:772–86.
64. Lo Sasso G, Ryu D, Mouchiroud L, Fernando SC, Anderson CL, Katsyuba E, et al. Loss of Sirt1 function improves intestinal anti-bacterial defense and protects from colitis-induced colorectal cancer. *PLoS ONE.* 2014;9:e102495.
65. Eskandarian HA, Impens F, Nahori M-A, Soubigou G, Coppée J-Y, Cossart P, et al. A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection. *Science.* 2013;341:1238858.
66. Pereira JM, Chevalier C, Chaze T, Gianetto Q, Impens F, Matondo M, et al. Infection Reveals a Modification of SIRT2 Critical for Chromatin Association. *Cell Rep.* 2018;23:1124–37.
67. Zhang X, Cao R, Niu J, Yang S, Zhao S, Li H. Molecular Basis for Hierarchical Histone De-B-Hydroxybutyrylation by Sirt3. *SSRN Electronic Journal [Internet].* 2018 [cited 2019 Oct 12]; Available from: <https://www.ssrn.com/abstract=3231848>
68. Yue F, Cheng Y, Breschi A, Vierstra J, Wu W, Ryba T, et al. A comparative encyclopedia of DNA elements in the mouse genome. *Nature.* 2014;515:355–64.
69. Qin Y, Roberts JD, Grimm SA, Lih FB, Deterding LJ, Li R, et al. An obesity-associated gut microbiome reprograms the intestinal epigenome and leads to altered colonic gene expression. *Genome Biol.* 2018;19:7.

70. Cooke J, Zhang H, Greger L, Silva A-L, Massey D, Dawson C, et al. Mucosal genome-wide methylation changes in inflammatory bowel disease. *Inflamm Bowel Dis*. 2012;18:2128–37.
71. Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O’Leary KR, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. *Nat Commun*. 2016;7:13507.
72. McDermott E, Ryan EJ, Tosetto M, Gibson D, Burrage J, Keegan D, et al. DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis. *J Crohns Colitis*. 2016;10:77–86.
73. Harris RA, Shah R, Hollister EB, Tronstad RR, Hovdenak N, Szigeti R, et al. Colonic Mucosal Epigenome and Microbiome Development in Children and Adolescents. *J Immunol Res*. 2016;2016:9170162.
74. Lin Z, Hegarty J, Cappel J, Yu W, Chen X, Faber P, et al. Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. *Clinical Genetics*. 2011;80:59–67.
75. Kelly D, Kotliar M, Woo V, Jagannathan S, Whitt J, Moncivaiz J, et al. Microbiota-sensitive epigenetic signature predicts inflammation in Crohn’s disease. *JCI Insight*. 2018;3.
76. Chen K, Luan X, Liu Q, Wang J, Chang X, Snijders AM, et al. Drosophila Histone Demethylase KDM5 Regulates Social Behavior through Immune Control and Gut Microbiota Maintenance. *Cell Host Microbe*. 2019;25:537-552.e8.
77. Farrelly LA, Thompson RE, Zhao S, Lepack AE, Lyu Y, Bhanu NV, et al. Histone seronylation is a permissive modification that enhances TFIID binding to H3K4me3. *Nature*. 2019;567:535–9.
78. Konev AY, Tribus M, Park SY, Podhraski V, Lim CY, Emelyanov AV, et al. CHD1 motor protein is required for deposition of histone variant H3.3 into chromatin in vivo. *Science*. 2007;317:1087–90.
79. Sebald J, Morettini S, Podhraski V, Lass-Flörl C, Lusser A. CHD1 contributes to intestinal resistance against infection by *P. aeruginosa* in *Drosophila melanogaster*. *PLoS ONE*. 2012;7:e43144.
80. Sebald J, Willi M, Schoberleitner I, Krogsdam A, Orth-Höller D, Trajanoski Z, et al. Impact of the Chromatin Remodeling Factor CHD1 on Gut Microbiome Composition of *Drosophila melanogaster*. *PLoS ONE*. 2016;11:e0153476.
81. Goodrich JK, Di Rienzi SC, Poole AC, Koren O, Walters WA, Caporaso JG, et al. Conducting a microbiome study. *Cell*. 2014;158:250–62.
82. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. *Cell*. 2014;159:789–99.

83. Roy U, Gálvez EJC, Iljazovic A, Lesker TR, Błażejowski AJ, Pils MC, et al. Distinct Microbial Communities Trigger Colitis Development upon Intestinal Barrier Damage via Innate or Adaptive Immune Cells. *Cell Reports*. 2017;21:994–1008.
84. Beura LK, Hamilton SE, Bi K, Schenkel JM, Odumade OA, Casey KA, et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. *Nature*. 2016;532:512–6.
85. Rosshart SP, Herz J, Vassallo BG, Hunter A, Wall MK, Badger JH, et al. Laboratory mice born to wild mice have natural microbiota and model human immune responses. *Science*. 2019;365.
86. Rosshart SP, Vassallo BG, Angeletti D, Hutchinson DS, Morgan AP, Takeda K, et al. Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance. *Cell*. 2017;171:1015-1028.e13.
87. Heil BA, Paccamonti DL, Sones JL. Role for the mammalian female reproductive tract microbiome in pregnancy outcomes. *Physiol Genomics*. 2019;51:390–9.
88. Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. *Cold Spring Harb Perspect Med*. 2016;6.
89. Jenuwein T, Allis CD. Translating the histone code. *Science*. 2001;293:1074–80.
90. Clevers H, Batlle E. SnapShot: the intestinal crypt. *Cell*. 2013;152:1198-1198.e2.
91. Hansson GC. Role of mucus layers in gut infection and inflammation. *Curr Opin Microbiol*. 2012;15:57–62.
92. Rao JN, Wang J-Y. Regulation of Gastrointestinal Mucosal Growth [Internet]. San Rafael (CA): Morgan & Claypool Life Sciences; 2010 [cited 2019 Oct 12]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK54091/>
93. Wang J, Thingholm LB, Skiecevičienė J, Rausch P, Kummén M, Hov JR, et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. *Nat Genet*. 2016;48:1396–406.
94. Wostmann BS. The germfree animal in nutritional studies. *Annu Rev Nutr*. 1981;1:257–79.
95. Sumi Y, Miyakawa M, Kanzaki M, Kotake Y. Vitamin B-6 deficiency in germfree rats. *J Nutr*. 1977;107:1707–14.
96. Yoshii K, Hosomi K, Sawane K, Kunisawa J. Metabolism of Dietary and Microbial Vitamin B Family in the Regulation of Host Immunity. *Front Nutr*. 2019;6:48.
97. Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V, Thiele I. Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. *Front Genet*. 2015;6:148.

98. Suttie JW. The importance of menaquinones in human nutrition. *Annu Rev Nutr.* 1995;15:399–417.
99. Connors J, Dawe N, Van Limbergen J. The Role of Succinate in the Regulation of Intestinal Inflammation. *Nutrients.* 2018;11.
100. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. *Curr Opin Gastroenterol.* 2014;30:332–8.
101. Nicholson JK, Wilson ID. Opinion: understanding “global” systems biology: metabonomics and the continuum of metabolism. *Nat Rev Drug Discov.* 2003;2:668–76.
102. Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, et al. Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. *Cell Metab.* 2018;28:737-749.e4.
103. Ozdal T, Sela DA, Xiao J, Boyacioglu D, Chen F, Capanoglu E. The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility. *Nutrients.* 2016;8:78.
104. Rajavelu A, Tulyasheva Z, Jaiswal R, Jeltsch A, Kuhnert N. The inhibition of the mammalian DNA methyltransferase 3a (Dnmt3a) by dietary black tea and coffee polyphenols. *BMC Biochem.* 2011;12:16.
105. Nandakumar V, Vaid M, Katiyar SK. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. *Carcinogenesis.* 2011;32:537–44.
106. Vahid F, Zand H, Nosrat-Mirshekarlou E, Najafi R, Hekmatdoost A. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review. *Gene.* 2015;562:8–15.
107. Takagaki A, Nanjo F. Catabolism of (+)-catechin and (-)-epicatechin by rat intestinal microbiota. *J Agric Food Chem.* 2013;61:4927–35.
108. Winter J, Moore LH, Dowell VR, Bokkenheuser VD. C-ring cleavage of flavonoids by human intestinal bacteria. *Appl Environ Microbiol.* 1989;55:1203–8.
109. Miyamoto J, Igarashi M, Watanabe K, Karaki S-I, Mukouyama H, Kishino S, et al. Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. *Nat Commun.* 2019;10:4007.
110. Miyamoto J, Mizukure T, Park S-B, Kishino S, Kimura I, Hirano K, et al. A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. *J Biol Chem.* 2015;290:2902–18.
111. Kishino S, Takeuchi M, Park S-B, Hirata A, Kitamura N, Kunisawa J, et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. *Proc Natl Acad Sci USA.* 2013;110:17808–13.

112. Nanthirudjanar T, Furumoto H, Zheng J, Kim Y-I, Goto T, Takahashi N, et al. Gut Microbial Fatty Acid Metabolites Reduce Triacylglycerol Levels in Hepatocytes. *Lipids*. 2015;50:1093–102.
113. Ohue-Kitano R, Yasuoka Y, Goto T, Kitamura N, Park S-B, Kishino S, et al. α -Linolenic acid-derived metabolites from gut lactic acid bacteria induce differentiation of anti-inflammatory M2 macrophages through G protein-coupled receptor 40. *FASEB J*. 2018;32:304–18.
114. Dimri M, Bommi PV, Sahasrabudde AA, Khandekar JD, Dimri GP. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. *Carcinogenesis*. 2010;31:489–95.
115. Dumas M-E, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. *Proc Natl Acad Sci USA*. 2006;103:12511–6.
116. Kaelin WG, McKnight SL. Influence of metabolism on epigenetics and disease. *Cell*. 2013;153:56–69.
117. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of α -KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. *Genes Dev*. 2012;26:1326–38.
118. Rath S, Heidrich B, Pieper DH, Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. *Microbiome*. 2017;5:54.
119. Nag A, St John PC, Crowley MF, Bomble YJ. Prediction of reaction knockouts to maximize succinate production by *Actinobacillus succinogenes*. *PLoS ONE*. 2018;13:e0189144.
120. Serena C, Ceperuelo-Mallafre V, Keiran N, Queipo-Ortuño MI, Bernal R, Gomez-Huelgas R, et al. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. *ISME J*. 2018;12:1642–57.
121. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. *Nat Rev Microbiol*. 2014;12:661–72.
122. Abdul Rahim MBH, Chilloux J, Martinez-Gili L, Neves AL, Myridakis A, Gooderham N, et al. Diet-induced metabolic changes of the human gut microbiome: importance of short-chain fatty acids, methylamines and indoles. *Acta Diabetol*. 2019;56:493–500.
123. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. *Proc Natl Acad Sci USA*. 2008;105:16767–72.
124. Cousens LS, Gallwitz D, Alberts BM. Different accessibilities in chromatin to histone acetylase. *J Biol Chem*. 1979;254:1716–23.

125. Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, et al. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. *ISME J.* 2014;8:1323–35.
126. Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, et al. Acetate mediates a microbiome-brain- β -cell axis to promote metabolic syndrome. *Nature.* 2016;534:213–7.
127. Fukuda S, Toh H, Taylor TD, Ohno H, Hattori M. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. *Gut Microbes.* 2012;3:449–54.
128. Feng W, Ao H, Peng C. Gut Microbiota, Short-Chain Fatty Acids, and Herbal Medicines. *Front Pharmacol.* 2018;9:1354.
129. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS Microbiol Lett.* 2009;294:1–8.
130. Walker AW, Duncan SH, McWilliam Leitch EC, Child MW, Flint HJ. pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. *Appl Environ Microbiol.* 2005;71:3692–700.
131. Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. *Annu Rev Med.* 2011;62:361–80.
132. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. *Proc Natl Acad Sci USA.* 2014;111:2247–52.
133. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. *Science.* 2012;336:1262–7.
134. Levy M, Kolodziejczyk AA, Thaïss CA, Elinav E. Dysbiosis and the immune system. *Nat Rev Immunol.* 2017;17:219–32.
135. Berndsen CE, Denu JM. Catalysis and substrate selection by histone/protein lysine acetyltransferases. *Curr Opin Struct Biol.* 2008;18:682–9.
136. Lange M, Kaynak B, Forster UB, Tönjes M, Fischer JJ, Grimm C, et al. Regulation of muscle development by DPF3, a novel histone acetylation and methylation reader of the BAF chromatin remodeling complex. *Genes Dev.* 2008;22:2370–84.
137. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. *Nat Rev Drug Discov.* 2014;13:337–56.
138. Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. *Cell.* 2014;159:558–71.
139. Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. *Nat Rev Mol Cell Biol.* 2019;20:156–74.

140. Chen Y, Sprung R, Tang Y, Ball H, Sangras B, Kim SC, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. *Mol Cell Proteomics*. 2007;6:812–9.
141. Montgomery DC, Sorum AW, Meier JL. Defining the orphan functions of lysine acetyltransferases. *ACS Chem Biol*. 2015;10:85–94.
142. Han Z, Wu H, Kim S, Yang X, Li Q, Huang H, et al. Revealing the protein propionylation activity of the histone acetyltransferase MOF (males absent on the first). *J Biol Chem*. 2018;293:3410–20.
143. Leemhuis H, Packman LC, Nightingale KP, Hollfelder F. The human histone acetyltransferase P/CAF is a promiscuous histone propionyltransferase. *Chembiochem*. 2008;9:499–503.
144. Kaczmarek Z, Ortega E, Goudarzi A, Huang H, Kim S, Márquez JA, et al. Structure of p300 in complex with acyl-CoA variants. *Nat Chem Biol*. 2017;13:21–9.
145. Flynn EM, Huang OW, Poy F, Oppikofer M, Bellon SF, Tang Y, et al. A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications. *Structure*. 2015;23:1801–14.
146. Xiong X, Panchenko T, Yang S, Zhao S, Yan P, Zhang W, et al. Selective recognition of histone crotonylation by double PHD fingers of MOZ and DPF2. *Nat Chem Biol*. 2016;12:1111–8.
147. Feldman JL, Baeza J, Denu JM. Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. *J Biol Chem*. 2013;288:31350–6.
148. Sabari BR, Tang Z, Huang H, Yong-Gonzalez V, Molina H, Kong HE, et al. Intracellular crotonyl-CoA stimulates transcription through p300-catalyzed histone crotonylation. *Mol Cell*. 2015;58:203–15.
149. Liu X, Wei W, Liu Y, Yang X, Wu J, Zhang Y, et al. MOF as an evolutionarily conserved histone crotonyltransferase and transcriptional activation by histone acetyltransferase-deficient and crotonyltransferase-competent CBP/p300. *Cell Discov*. 2017;3:17016.
150. Zhao D, Guan H, Zhao S, Mi W, Wen H, Li Y, et al. YEATS2 is a selective histone crotonylation reader. *Cell Res*. 2016;26:629–32.
151. Bao X, Wang Y, Li X, Li X-M, Liu Z, Yang T, et al. Identification of “erasers” for lysine crotonylated histone marks using a chemical proteomics approach. *Elife*. 2014;3.
152. Madsen AS, Olsen CA. Profiling of substrates for zinc-dependent lysine deacylase enzymes: HDAC3 exhibits decrotonylase activity in vitro. *Angew Chem Int Ed Engl*. 2012;51:9083–7.

Highlights

Chromatin dynamics and histone modifications in the intestinal microbiota-host crosstalk

Rachel Fellows¹ and Patrick Varga-Weisz^{1,2}

1: Babraham Institute, Babraham, Cambridge CB22 3AT, UK

2: School of Life Sciences, University of Essex, Colchester, CO4 3SQ, UK

Correspondence: Patrick.varga-weisz@essex.ac.uk

- Chromatin dynamics of the host epithelium involving histone modifications play an important role in host-microbiota crosstalk
- Microbiota-derived short chain fatty acids (SCFA) are a dominant determinant in microbiome-host interaction and the inhibition of histone deacetylases (HDACs) by SCFA is a key mechanism in this process.
- Alternative histone acylations, such as crotonylation, reveal a new layer of complexity in host-microbiota crosstalk.